Kite Pharma

Kite Pharma is a global biotechnology company based in Santa Monica, California, specializing in cell therapy for cancer treatment. Founded in 2009 and acquired by Gilead Sciences in 2017, Kite operates as a leader in the field of cell therapy, utilizing patients' own immune cells to combat cancer. The company focuses on developing genetically engineered autologous CAR T cell therapies, including its lead product, Yescarta, which is the first CAR-T therapy approved by the FDA for adult patients with relapsed or refractory large B-cell lymphoma. Kite manufactures its therapies at three global facilities, including a significant site in Hoofddorp, Netherlands, which has the capacity to produce up to 4,000 treatments annually. Kite collaborates with over 300 hospitals across 23 countries to provide its innovative therapies to patients. The company's research and development efforts are dedicated to advancing immunotherapy approaches for various blood cancers and solid tumors, building on foundational research from the U.S. National Cancer Institute.